Neural precursor cells induce cell death of high-grade astrocytomas via stimulation of TRPV1

Primary astrocytomas of World Health Organization grade 3 and grade 4 (HG-astrocytomas) are preponderant among adults and are almost invariably fatal despite multimodal therapy. Here, we show that the juvenile brain has an endogenous defense mechanism against HG-astrocytomas. Neural precursor cells...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature medicine 2012-07, Vol.18 (8), p.1232-1238
Hauptverfasser: Stock, Kristin, Kumar, Jitender, Synowitz, Michael, Petrosino, Stefania, Imperatore, Roberta, Smith, Ewan St. J., Wend, Peter, Purfürst, Bettina, Nuber, Ulrike A., Gurok, Ulf, Matyash, Vitali, Wälzlein, Joo-Hee, Chirasani, Sridhar R., Dittmar, Gunnar, Cravatt, Benjamin F., Momma, Stefan, Lewin, Gary R., Ligresti, Alessia, De Petrocellis, Luciano, Cristino, Luigia, Di Marzo, Vincenzo, Kettenmann, Helmut, Glass, Rainer
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Primary astrocytomas of World Health Organization grade 3 and grade 4 (HG-astrocytomas) are preponderant among adults and are almost invariably fatal despite multimodal therapy. Here, we show that the juvenile brain has an endogenous defense mechanism against HG-astrocytomas. Neural precursor cells (NPCs) migrate to HG-astrocytomas, reduce glioma expansion and prolong survival by releasing a group of fatty acid ethanolamides that have agonistic activity on the vanilloid receptor (transient receptor potential vanilloid subfamily member-1; TRPV1). TRPV1 expression is higher in HG-astrocytomas than in tumor-free brain and TRPV1 stimulation triggers tumor cell death via the activating transcription factor-3 (ATF3) controlled branch of the ER stress pathway. The anti-tumorigenic response of NPCs is lost with aging. NPC-mediated tumor suppression can be mimicked in the adult brain by systemic administration of the synthetic vanilloid Arvanil, suggesting that TRPV1 agonists hold potential as new HG-astrocytoma therapeutics.
ISSN:1078-8956
1546-170X
DOI:10.1038/nm.2827